Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
RHOA,
IDH2,
TET2,
ATM,
CD58,
DNMT3A,
B2M,
FYN,
CD28,
NECTIN2,
RC3H1,
NOS2,
NCAM1,
NOS1,
TRBV20OR9-2,
TNFRSF8,
ALK,
SYK,
ITK,
KRT20,
MS4A1,
CD274,
GATA3,
STAT5B,
MME,
TP53,
PDLIM7,
PDGFRA,
IRF4,
IGH
RHOA,
IDH2,
TET2,
ATM,
CD58,
DNMT3A,
B2M,
FYN,
CD28,
NECTIN2,
RC3H1,
NOS2,
NCAM1,
NOS1,
TRBV20OR9-2,
TNFRSF8,
ALK,
SYK,
ITK,
KRT20,
MS4A1,
CD274,
GATA3,
STAT5B,
MME,
TP53,
PDLIM7,
PDGFRA,
IRF4,
IGH,
STAT3,
STAT5A,
FGFR3,
TBX21,
SMUG1,
BCL6,
MCL1,
FOXP1,
TCL1A,
IL2,
CHP1,
TP63,
AKT1,
PIK3CG,
HAVCR2,
PIK3CD,
JAK3,
HDAC9,
TCL1B,
CCR4,
PIK3CB,
PIK3CA,
PAX5,
NFKB1,
VAV1,
VEGFA,
TNF,
ETV6,
CD52,
DDIT3,
BCL2,
CD79A,
CDK6,
CDKN2A,
FER,
TNFSF10,
TEK,
RHOV,
TERT,
STX11,
TFPI,
TIA1,
TLR4,
SNORD71,
SMTNL1,
MIR187,
SKAP1,
MALAT1,
TM7SF2,
ZAP70,
YY1,
BCL10,
TMOD1,
ARHGEF7,
DUSP22,
NAPRT,
TRB,
RHOJ,
RTEL1,
POLK,
LEF1,
ASCC1,
TSPYL2,
COL18A1,
LBH,
TRBC1,
TRBV7-9,
TRBV16,
DLL1,
PART1,
CADM1,
ISCU,
SNORD14E,
SNORD35B,
PHB2,
GLIS2,
DCTN3,
CD226,
CXCL13,
CLEC10A,
PWWP3A,
NAPSA,
SNORD14B,
GRAP2,
SNORD14C,
DOK2,
SNORD14D,
ACVRL1,
PRKCB,
TRA,
ERBB4,
CDKN2B,
CHEK1,
CSF2,
CYP3A4,
DYNC1H1,
EGR1,
EZH2,
CDK7,
PTK2B,
FKBP4,
GEM,
CXCR3,
GZMB,
HDAC1,
CDKN1B,
CD68,
HDC,
CASP8,
ALB,
ANGPT1,
CCND1,
BCL3,
CXCR5,
BMI1,
CAV1,
CD44,
CCNA2,
CD1D,
CD14,
CD86,
CD37,
CD40,
HDAC2,
HPR,
TCOF1,
SCT,
PTPN2,
PTPN6,
RARA,
SNORD15A,
RPL18A,
S100A7,
SLPI,
PIM1,
SMARCB1,
SOAT1,
STK10,
TAP2,
HNF1A,
TCF7,
PSMB6,
NRAS,
ID2,
IL13,
IDH1,
IFNG,
IL2RB,
IL2RG,
IL4,
IL6,
LAG3,
PNP,
LGALS1,
LTA,
MTAP,
MYO1F,
MYC,
NOTCH1,
H3P40
Drugs
A-dmDT390-bisFv(UCHT1),
Adenovirus-Interferon gamma - coding DNA sequence,
Alisertib,
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Belinostat
(
BELEODAQ
),
Brentuximab vedotin
(
ADCETRIS
),
Chlormethine
(
Ledaga
),
Darinaparsin,
Denileukin diftitox,
Fenretinide,
Forodesine hydrochloride,
Human monoclonal antibody against CD4,
Humanised IgG1 monoclonal antibody against human KIR3DL2,
Iodine (131I) tositumomab,
Miltefosine
(
IMPAVIDO
),
Mogamulizumab
(
POTELIGEO
),
N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide,
Naloxone hydrochloride dihydrate,
Panobinostat
(
FARYDAK
),
Pralatrexate
(
FOLOTYN
),
Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein,
Resiquimod,
Romidepsin
(
ISTODAX
),
Siplizumab,
Suberolylanilide hydroxamic acid,
Synthetic hypericin,
Vorinostat
(
ZOLINZA
),
Zanolimumab,
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
Registered!
An extremely rare, primary cutaneous T-cell lymphoma disorder characterized by solitary, or multifocal and diffuse, cutaneous lesions, ranging from tumor-like patches, plaques, papules, nodules, and/or erythroderma, located on any area of the body, which rapidly progress and may become ulcerated and/or infected. Systemic involvement may be associated.